With reference to a randomized controlled trial, briefly describe the terms “blinding” and “allocation concealment”.
• Blinding and allocation concealment are methods used to reduce bias in clinical trials.
• Blinding: a process by which trial participants and their relatives, care-givers, data collectors and those adjudicating outcomes are unaware of which treatment is being given to the individual participants.
- Prevents clinicians from consciously or subconsciously treating patients differently based on treatment allocation
- Prevents data collectors from introducing bias when there is a subjective assessment to be made for eg “pain score”
- Prevents outcome assessors from introducing bias when there is a subjective outcome assessment to be made for eg Glasgow outcome score.
• Traditionally, blinded RCTs have been classified as "single-blind," "double-blind," or "triple-blind"; The 2010 CONSORT Statement specifies that authors and editors should not use the terms "single-blind," "double-blind," and "triple-blind"; instead, reports of blinded RCT should discuss "If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how.
Allocation concealment is an important component of the randomization process and refers to the concealment of the allocation of the randomization sequence from both the investigators and the patient. Poor allocation concealment may potential exaggerate treatment effects.
Methods used for allocation concealment include sealed envelope technique, telephone or web based randomization.
Allocation concealment effectively ensures that the treatment to be allocated is not known before the patient is entered into the study. Blinding ensures that the patient / physician is blinded to the treatment allocation after enrollment into the study.
The question is a 10-mark question, but it for some reason asks for one to "briefly describe" these concepts. Judging from the college answer, a truly brief description was not the expected response.
LITFL has a thorough summary, which is not brief.
If one were to briefly describe these concepts, one would produce something like this:
- Ensures that the patients and investigators cannot predict which treatment will be allocated to which patient before they are enrolled in the study.
- Prevents selection bias
- Ensures that the patients and investigators remain unaware of which treatment is being administered to which idividual patient.
- Prevents detection bias and observer bias
And if one were to go to town on this topic, one would produce something like this:
Schulz, Kenneth F., and David A. Grimes. "Allocation concealment in randomised trials: defending against deciphering." The Lancet 359.9306 (2002): 614-618.
Forder, Peta M., Val J. Gebski, and Anthony C. Keech. "Allocation concealment and blinding: when ignorance is bliss." Med J Aust 182.2 (2005): 87-9.
Schulz, Kenneth F. "Assessing allocation concealment and blinding in randomised controlled trials: why bother?." Evidence Based Mental Health 3.1 (2000): 4-5.